LEADER 01886nam  2200385z- 450 
001 9910758478403321
005 20231031
035   $a(CKB)5720000000254700
035   $a(oapen)doab121168
035   $a(EXLCZ)995720000000254700
100   $a20231121c2023uuuu  -u-         -
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aClinical Relevance of Brain Atrophy Measures in Multiple Sclerosis
210   $aPrague$cKarolinum Press$d2023
215   $a1 online resource (83 p.)
311 08$a80-246-5692-2 
330   $aMagnetic resonance imaging of the brain and spinal cord in patients with multiple sclerosis is crucial for diagnosis as well as monitoring and predicting disease activity. Comprehensive MR measurements including assessment of brain and spinal cord volume changes have the potential to improve patient monitoring, allow earlier detection of subclinical disease activity, and identify patients with depleted brain reserve who are at highest risk of disability progression. Cerebral atrophy measurements are now a secondary outcome of many clinical trials, although their wider use in routine clinical practice is still hampered by some technical limitations. However, evidence from clinical practice shows that assessment of brain and spinal cord volume change is feasible and has the potential to improve patient treatment.
606   $aMedicine$2bicssc
610   $abrain atrophy
610   $acerebral atrophy
610   $adiagnosis
610   $adisease
610   $amagnetic resonance
610   $ameasurements
610   $amonitoring
610   $amultiple sclerosis
615  7$aMedicine
906   $aBOOK
912   $a9910758478403321
996   $aClinical Relevance of Brain Atrophy Measures in Multiple Sclerosis$93599743
997   $aUNINA